NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has signed a supply and distribution agreement enabling it to offer its customers access to Sirion Biotech's RNAiONE custom short hairpin RNA development services.

In addition, Cambridge, UK-based Horizon said that it also would offer Sirion's off-the-shelf shRNA and cDNA over-expression reagents. It said the reagents would be available as transduction-ready lentivirus particles or as plasmids.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.